Deng Rui-Ming, Huang Guiming, Wang Tingting, Zhou Juan
Department of Anesthesiology, Ganzhou People's Hospital, 16 Meiguan Avenue, Ganzhou, Jiangxi Province 341000, PR China.
Department of Anesthesiology, Ganzhou People's Hospital, 16 Meiguan Avenue, Ganzhou, Jiangxi Province 341000, PR China.
Int Immunopharmacol. 2025 Feb 20;148:114111. doi: 10.1016/j.intimp.2025.114111. Epub 2025 Jan 19.
Sepsis associated acute lung injury (SALI) is a common complication in patients with severe sepsis and a disease with high morbidity and mortality in ICU patients. The main mechanism of SALI is pulmonary hypoperfusion due to hypotension and shock caused by sepsis, which leads to ischemic necrosis of alveolar endothelial cells and eventually lung failure. At present, SALI therapy mainly includes antibiotic therapy, fluid resuscitation, transfusion products and vasoactive drugs, but these strategies are not satisfactory. Therefore, focusing on the role of different cell death patterns in SALI may help in the search for effective treatments. Understanding the molecular mechanisms of SALI and identifying pathways that inhibit lung cell death are critical to developing effective drug therapies to prevent the progression of SALI. Cell death is controlled by programmed cell death (PCD) pathways, including apoptosis, necroptosis, ferroptosis, pyroptosis and autophagy. There is growing evidence that PCD plays an important role in the pathogenesis of SALI, and inhibitors of various types of PCD represent a promising therapeutic strategy. Therefore, understanding the role and mechanism of PCD in SALI is conducive to our understanding of its pathological mechanism, and is of great significance for the treatment of SALI. In this article, we discuss recent advances in the role of PCD in SALI, show how different signaling pathways (such as NF-κB, PI3K/Akt, mTOR, and Nrf2) regulate PCD to regulate SALI development, and discuss the associations between various types of PCD. The aim is to explore the molecular mechanism behind SALI and to find new targets for SALI therapy.
脓毒症相关急性肺损伤(SALI)是重症脓毒症患者常见的并发症,也是重症监护病房(ICU)患者中发病率和死亡率较高的一种疾病。SALI的主要机制是脓毒症引起的低血压和休克导致肺灌注不足,进而导致肺泡内皮细胞缺血坏死,最终导致肺功能衰竭。目前,SALI的治疗主要包括抗生素治疗、液体复苏、输血制品和血管活性药物,但这些策略并不令人满意。因此,关注不同细胞死亡模式在SALI中的作用可能有助于寻找有效的治疗方法。了解SALI的分子机制并确定抑制肺细胞死亡的途径对于开发有效的药物治疗以防止SALI进展至关重要。细胞死亡受程序性细胞死亡(PCD)途径控制,包括细胞凋亡、坏死性凋亡、铁死亡、焦亡和自噬。越来越多的证据表明,PCD在SALI的发病机制中起重要作用,各种类型PCD的抑制剂代表了一种有前景的治疗策略。因此,了解PCD在SALI中的作用和机制有助于我们理解其病理机制,对SALI的治疗具有重要意义。在本文中,我们讨论了PCD在SALI中作用的最新进展,展示了不同的信号通路(如NF-κB、PI3K/Akt、mTOR和Nrf2)如何调节PCD以调控SALI的发展,并讨论了各种类型PCD之间的关联。目的是探索SALI背后的分子机制,并寻找SALI治疗的新靶点。